MDGL Stock Cash Flow Statements

Madrigal Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Madrigal Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-06-30	2010-03-31	2009-09-30

cash flows from operating activities:
net income	-42,281,000	-73,238,000	-59,416,000	-106,964,000	-151,971,000	-147,541,000	-112,194,000	-98,740,000	-85,800,000	-76,896,000	-85,905,000	-81,197,000	-70,730,000	-57,518,000	-64,549,000	-63,100,000	-61,651,000	-52,546,000	-59,123,000	-57,963,000	-49,023,000	-36,135,000	-27,740,000	-21,429,000	-19,699,000	-15,080,000	-8,512,000	-6,460,000	-6,364,000	-8,363,000	-8,347,000	-5,999,000	-8,735,589	-3,379,000	-6,524,000	-17,628,000	-19,800,000	-20,707,000	-19,966,000	-22,286,000	-23,557,000	-22,515,000	-22,787,000	-20,728,000	-14,996,000	-14,620,000	-15,051,000	-12,734,000	-12,502,000	-11,401,000	-9,074,000	-9,308,000	119,220,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	25,159,000	20,931,000	17,676,000	17,898,000	24,404,000	19,902,000	14,852,000	12,660,000	10,973,000	11,250,000	8,082,000	8,122,000	7,944,000	7,477,000	6,356,000	6,242,000	8,179,000	6,096,000	5,134,000	5,061,000	5,689,000	4,846,000	4,032,000	4,950,000	7,755,000	6,022,000	4,976,000	2,227,000	1,167,000	1,029,000	676,000	602,000		545,000	448,000	1,168,000	843,000	1,710,000	1,566,000	1,513,000	2,586,000	1,683,000	1,591,000	1,216,000	801,000	731,000	827,000	867,000	812,000	827,000	1,135,000	1,087,000
depreciation and amortization expense	377,000	379,000	363,000	298,000	267,000	168,000	142,000	135,000	126,000	124,000	129,000	121,000	110,000	107,000	106,000	97,000	89,000	113,000	116,000	115,000	115,000	125,000	28,000	28,000	28,000	28,000	24,000	24,000	23,000	9,000
amortization of debt issuance costs and discount	371,000	436,000	482,000	480,000	472,000	655,000	753,000	674,000	554,000	433,000	306,000	313,000
amortization and interest accretion related to operating leases	55,000	56,000	58,000
other non-cash items
changes in operating assets and liabilities:
trade receivables	-17,803,000	-7,606,000	-23,359,000	-23,564,000
prepaid expenses and other current assets	-35,362,000	-9,456,000	7,075,000	-5,898,000	-928,000	-10,885,000	-32,000	59,000	-1,370,000	788,000	1,325,000	-1,140,000	-1,563,000	121,000	2,474,000	-1,591,000	-1,399,000	191,000	651,000	559,000	-1,247,000	175,000	561,000	677,000	-1,794,000	888,000			290,000	287,000	-517,000	520,000			647,000			289,000			153,000
inventory	-8,256,000	-21,173,000	-25,353,000	-1,643,000	-6,218,000	-854,000
accounts payable	-4,081,000	-1,543,000	-2,367,000	36,972,000	-7,534,000	-11,513,000	11,499,000	-992,000	5,406,000	-11,703,000	5,269,000	7,268,000	-11,486,000	1,400,000	10,962,000	9,351,000	-3,329,000	3,379,000	-5,260,000	1,273,000	3,889,000	-63,000	405,000	327,000	-3,930,000	1,889,000				115,000	-1,495,000	2,018,000						598,000						58,000	222,000			923,000
accrued liabilities	33,314,000	-530,000	-6,308,000
accrued interest, net of interest received on maturity of investments	513,000	2,853,000	-13,337,000	503,000	-9,878,000	-1,380,000	-2,323,000	435,000	-1,393,000	-2,169,000	416,000	-318,000	-207,000	106,000	53,000	184,000	65,000	485,000	1,086,000	280,000	640,000	-86,000	2,073,000	1,306,000
net cash from operating activities	-47,052,000	-88,891,000	-104,486,000	-66,984,000	-134,945,000	-149,157,000	-79,933,000	-84,920,000	-75,310,000	-84,067,000	-58,515,000	-59,069,000	-57,360,000	-49,913,000	-48,051,000	-45,556,000	-46,881,000	-43,429,000	-54,947,000	-47,850,000	-24,258,000	-30,506,000	-12,282,000	-11,324,000
capex	0	0	-195,000	-779,000	-131,000	-357,000	-1,036,000	-339,000	-69,000	-35,000	-29,000	-33,000	-103,000	-52,000	-113,000	-50,000	-2,000	-44,000	-10,000	-3,000	-7,000	-314,000	-134,000	2,000
free cash flows	-47,052,000	-88,891,000	-104,681,000	-67,763,000	-135,076,000	-149,514,000	-80,969,000	-85,259,000	-75,379,000	-84,102,000	-58,544,000	-59,102,000	-57,463,000	-49,965,000	-48,164,000	-45,606,000	-46,883,000	-43,473,000	-54,957,000	-47,853,000	-24,265,000	-30,820,000	-12,416,000	-11,322,000
cash flows from investing activities:
purchases of marketable securities	-225,534,000	-130,812,000	-350,186,000	-416,033,000	-280,791,000	-84,197,000	-474,890,000	-68,853,000	-91,874,000	-198,822,000	-12,785,000	-14,197,000	-78,929,000	-37,567,000	-54,749,000	-115,300,000	-130,349,000	-93,722,000	-116,156,000	-59,317,000	-95,222,000	-58,647,000	-212,230,000	-140,957,000
sales and maturities of marketable securities	273,392,000	294,690,000	302,431,000	214,421,000	163,824,000	182,607,000	113,803,000	119,391,000	88,211,000	11,993,000	79,201,000	79,367,000	98,268,000	93,545,000	70,505,000	155,441,000	103,026,000	60,302,000	111,368,000	154,073,000	114,594,000	109,421,000	181,857,000	169,222,000	128,716,000	170,387,000	51,051,000	48,763,000	20,071,000	-13,089,000	8,470,000	11,563,000	-32,246,154			37,186,000																	15,717,000
acquisition of intangible asset			0	0
purchases of property and equipment, net of disposals			-195,000	-779,000	-131,000	-357,000	-1,036,000	-339,000	-69,000	-35,000	-29,000	-33,000	-103,000	-52,000	-113,000	-50,000	-2,000	-44,000	-10,000	-3,000	-7,000	-314,000	-134,000	2,000
net cash from investing activities	47,858,000	163,878,000	-47,950,000	-202,391,000	-122,098,000	98,053,000	-362,123,000	50,199,000	-3,732,000	-186,864,000	66,387,000	65,137,000	19,236,000	55,926,000	15,643,000	40,091,000	-27,325,000	-33,464,000	-4,798,000	94,753,000	19,365,000	50,460,000	-30,507,000	28,267,000											22,381,000			8,317,000		11,478,000	16,197,000												-8,262,000
cash flows from financing activities:
proceeds from issuances of stock, excluding related parties, net of transaction costs		8,640,000	-23,000	0	85,949,000	311,561,000	235,703,000	2,730,000							18,958,000	21,092,000	63,541,000	66,616,000
proceeds from related parties - warrants, exercise of common stock options, net of transaction costs			19,794,000	7,462,000	48,174,000	262,145,000
net cash from financing activities	1,741,000	8,640,000	19,771,000	7,462,000	134,123,000	573,706,000	479,916,000	19,580,000	42,930,000	52,690,000	264,337,000	0			19,503,000	21,099,000	63,541,000	67,094,000	4,629,000	350,000			0	35,000	117,000	83,000	451,000	313,009,000	265,000	0	34,879,000	3,399,000				5,516,000			25,815,000	54,173,000	7,617,000	-211,000	120,000	12,280,000	23,951,000	441,000	33,050,000	-135,000	34,837,000	2,103,000	-247,000	26,351,000
net increase in cash, cash equivalents, and restricted cash	2,547,000	83,627,000		-261,913,000	-122,920,000	522,602,000
cash, cash equivalents, and restricted cash at beginning of period	0	105,019,000	0	0	0	99,915,000
cash, cash equivalents, and restricted cash at end of period	2,547,000	188,646,000	-132,665,000	-261,913,000	-122,920,000	622,517,000
supplemental disclosure of cash flow information:
obtaining a right-of-use asset in exchange for a lease liability			162,000				0				0	0			0	0			0				0	0
intangible assets in accounts payable at the end of the period						5,000,000
proceeds from issuance of loan payable							0	15,000,000	15,000,000	35,000,000	0	0
payment of debt issuance costs							0	-75,000	-75,000	-213,000	0	0
net increase in cash and cash equivalents							37,860,000	-15,141,000	-36,112,000	-218,241,000	272,209,000	6,068,000	10,990,000	6,013,000	-12,905,000	15,634,000	-10,665,000	-9,799,000	-55,116,000	47,253,000	-4,784,000	19,954,000	-42,789,000	16,978,000						-21,837,000					7,849,000				-28,333,000	44,777,000	3,544,000						4,475,000					13,762,000
accrued expense					23,340,000	2,291,000	7,370,000	849,000	-3,806,000	-5,894,000	11,863,000	7,762,000	18,394,000	-1,606,000	-3,453,000	3,261,000	11,165,000	-1,147,000			15,679,000	632,000	8,359,000	2,817,000						1,972,000
proceeds from the sale of related party warrants and stock and exercise of common stock options, net of transaction costs
cash and cash equivalents at beginning of period							0	0	0	331,549,000	0	0	0	36,269,000	0	0	0	54,004,000	0	0	0	46,697,000	0	0	0	57,379,000	0	0	148,627,000	0	0	19,145,000	-34,659,751	0	34,966,000	0	0	46,024,000	0	0	48,490,000	0	0	81,512,000	0	0	30,075,000	0	0	31,310,000	0	44,155,000	18,358,000
cash and cash equivalents at end of period							37,860,000	-15,141,000	-36,112,000	113,308,000	272,209,000	6,068,000	10,990,000	42,282,000	-12,905,000	15,634,000	-10,665,000	44,205,000	-55,116,000	47,253,000	-4,784,000	66,651,000	-42,789,000	16,978,000	25,015,000	47,493,000	-226,815,000	226,736,000	38,125,000	-21,837,000	26,582,000	8,215,000	-2,362,698	-32,059,000	42,815,000	13,534,000	-1,252,000	33,255,000	-28,333,000	44,777,000	52,034,000	-8,306,000	-1,179,000	34,962,000	3,849,000	-8,957,000	34,550,000	-5,248,000	8,519,000	17,372,000	-15,306,000	57,917,000	-29,723,000
proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs								1,925,000	6,251,000	17,903,000
proceeds from the exercise of common stock options																7,000								35,000
purchases of property and equipment in accounts payable at period end
proceeds from the exercise of common stock options, net of transaction costs																		478,000
accrued expenses
purchases of property and equipment in accounts payable or accrued expense at period end
proceeds from exercise of common stock options																										83,000	451,000
net decrease in cash and cash equivalents
acquisition of a right-of-use asset in exchange for a lease liability																										900,000
proceeds from issuance of stock, net of transaction costs																											0
proceeds from issuance of stock, net of transaction costs, including exercise of common stock options																													265,000
pik interest expense on convertible promissory notes payable — related parties
accounts receivable - related parties
accrued interest — related party
cash received from merger transaction
purchases of property and equipment
net proceeds from the sale of property, equipment and other assets
net cash provided (used) in investing activities
proceeds from issuance of common stock, net of transaction costs																																3,399,000
proceeds from convertible notes — related parties
exchange of related party advances payable for convertible notes
related party debt restructuring
proceeds from issuance of common and preferred stock, net of transaction costs
stock-based compensation expense and share based payments
other receivable — related parties
prepaid expense
net proceeds from the sale of property and equipment																																	216,440
net cash from in investing activities
proceeds from advances—related party
supplemental disclosure of non-cash financing activities:
depreciation and amortization																																		96,000	46,000	166,000	168,000	169,000	167,000	169,000	168,000	148,000	125,000	100,000	170,000	223,000	230,000	350,000	384,000	439,000	482,000	515,000	302,000
gain on disposal of property and equipment
other assets																																				52,000			27,000	26,000	32,000				37,000	16,000	112,000				0	207,000
accrued contract research costs																																				2,478,000	2,217,000	194,000	1,289,000	499,000	2,081,000	2,441,000	1,010,000	140,000	-57,000	-231,000	1,166,000	139,000	-382,000	742,000	-56,000	492,000
other accrued liabilities
proceeds from the sale of common stock to related parties, net of transaction costs																																							0
payment of term loans
payment of capital lease obligations
cash paid for interest																																		827,000	96,000	213,000	267,000	325,000	443,000	495,000	560,000	596,000	533,000	789,000	428,000	406,000	501,000	717,000	376,000	371,000	40,000	48,000	-10,000
maturities of marketable securities																																			31,600,000			37,000,000	15,250,000	25,670,000	19,768,000	18,408,000	25,009,000	18,950,000	16,500,000	3,695,000	9,650,000	14,302,000	11,000,000	11,342,000
net cash used by financing activities
proceeds from issuance of common stock, net of transaction costs, and exercise of common stock options																																				7,831,000			28,122,000	51,555,000	10,118,000
proceeds from the sale of common stock to related parties																																				0											5,000,000
proceeds from term loans																																										0	290,000	13,210,000				0
proceeds from issuance of common stock, excluding to related parties, and exercise of common stock options, net of transaction costs																																										11,000	26,000	1,045,000			28,204,000
collaboration receivable																																																0	0	116,000
deferred collaboration revenue
proceeds from the issuance of common stock, excluding to related parties, net of transaction costs																																													158,000
proceeds from the issuance of common stock to related parties																																													25,759,000
proceeds from issuance of common stock and exercise of common stock options, net of transaction costs																																																20,000	35,018,000	190,000	69,000	26,699,000
proceeds from term loan																																																		2,000,000
collaboration payable
supplemental disclosure of noncash operating, investing and financing activities:
acquisition of equipment under capital leases
restricted cash																																																					-389,000
proceeds from sale—leaseback of property and equipment
milestone payments receivable for product development milestones
in-process research and development
common stock issued for licenses
expense deferred offering costs
other stock-related compensation expense
changes in operating assets and liabilities, net of acquisitions:
deferred revenue
cash paid for acquisitions, net of cash acquired
advances issued to related parties
repayment of advances from related parties
proceeds from issuances of common stock and exercise of common stock warrants
proceeds from issuance of convertible preferred stock
proceeds from exercise of stock options
repurchase of common stock from officers
proceeds from sale-leaseback of property and equipment
payment of capital lease obligation
payment of deferred offering costs
supplemental disclosure of noncash investing and financing activities:
purchase of equipment under capital lease
convertible preferred stock beneficial conversion charge
convertible preferred stock dividends
conversion of preferred stock

We provide you with 20 years of cash flow statements for Madrigal Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Madrigal Pharmaceuticals stock. Explore the full financial landscape of Madrigal Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Madrigal Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.